Actively Recruiting
Phase 2 Study to Evaluate Safety and Dose Effects of MH002 in Mild-to-Moderate Ulcerative Colitis Not Controlled by 5-ASA
Led by MRM Health NV · Updated on 2026-10-21
204
Participants Needed
49
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of MH002, a live biotherapeutic product made of live bacteria, for treating mild-to-moderate ulcerative colitis UC. This condition causes inflammation and sores in the gut. The study aims to confirm previous findings and test two different doses of MH002 to understand its long-term effects on UC patients who have not fully responded to standard 5-aminosalicylic acid 5-ASA treatment. Participants will be randomly assigned to one of three groups low-dose MH002, high-dose MH002, or placebo. Both doses of MH002 consist of six wildtype commensal bacterial strains and are given orally once daily in capsule form. The study will last at least 12 weeks, focusing on the induction phase, during which researchers will monitor treatment effects and safety. During the study, participants will undergo assessments including endoscopic exams to measure changes in the gut lining, histologic evaluations, fecal calprotectin tests, and symptom scores to assess disease activity. Safety and tolerability will also be closely monitored. The primary outcome is the change in Mayo Endoscopic Subscore at Week 12. Participants will be followed throughout the treatment phase, which helps researchers understand how MH002 affects UC over time.
CONDITIONS
Brief Title
Confirmatory Clinical Study in Active Ulcerative Colitis
Research Team
E
Els Callebaut
C
Carmen Fleurinck, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here